WO2008017827A3 - Azole and thiazole derivatives and their uses - Google Patents

Azole and thiazole derivatives and their uses Download PDF

Info

Publication number
WO2008017827A3
WO2008017827A3 PCT/GB2007/002992 GB2007002992W WO2008017827A3 WO 2008017827 A3 WO2008017827 A3 WO 2008017827A3 GB 2007002992 W GB2007002992 W GB 2007002992W WO 2008017827 A3 WO2008017827 A3 WO 2008017827A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
azole
thiazole derivatives
diseases
respiritory
Prior art date
Application number
PCT/GB2007/002992
Other languages
French (fr)
Other versions
WO2008017827A2 (en
Inventor
Harry Finch
Richard James Bull
Jonathan Mark Sutton
Original Assignee
Argenta Discovery Ltd
Harry Finch
Richard James Bull
Jonathan Mark Sutton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2006/002956 external-priority patent/WO2007017669A1/en
Priority claimed from GB0702383A external-priority patent/GB0702383D0/en
Application filed by Argenta Discovery Ltd, Harry Finch, Richard James Bull, Jonathan Mark Sutton filed Critical Argenta Discovery Ltd
Publication of WO2008017827A2 publication Critical patent/WO2008017827A2/en
Publication of WO2008017827A3 publication Critical patent/WO2008017827A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention provides compounds of formula (Ia): wherein A, X, and R1-R8 are as defined herein, such compounds having utility in the treatment of diseases where M3 and beta2 receptors are implicated, such as respiritory tract diseases; compositions comprising such compounds; uses of such compounds in therapy (such as asthma or COPD); and methods of treating a patient with such compounds.
PCT/GB2007/002992 2006-08-08 2007-08-07 Azole and thiazole derivatives and their uses WO2008017827A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2006/002956 WO2007017669A1 (en) 2005-08-08 2006-08-08 Azole and thiazole derivatives and their use
GBPCT/GB2006/002956 2006-08-08
GB0702383A GB0702383D0 (en) 2007-02-07 2007-02-07 Chemical compound
GB0702383.1 2007-02-07

Publications (2)

Publication Number Publication Date
WO2008017827A2 WO2008017827A2 (en) 2008-02-14
WO2008017827A3 true WO2008017827A3 (en) 2008-04-03

Family

ID=38926156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002992 WO2008017827A2 (en) 2006-08-08 2007-08-07 Azole and thiazole derivatives and their uses

Country Status (1)

Country Link
WO (1) WO2008017827A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0702416D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702414D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
GB0702382D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
GB0702385D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
WO2008096129A1 (en) * 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
MX2009008364A (en) * 2007-02-07 2009-08-20 Astrazeneca Ab New salt.
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
WO2010015792A1 (en) * 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (en) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
SG11201504452WA (en) 2012-12-18 2015-07-30 Almirall Sa New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
AU2015301891B2 (en) 2014-08-11 2019-12-05 Angion Biomedica Corporation Cytochrome P450 inhibitors and uses thereof
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
MY196804A (en) 2016-12-14 2023-05-03 Beijing Showby Pharmaceutical Co Ltd Class of bifunctional compounds with quaternary ammonium salt structure

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307141A2 (en) * 1987-09-10 1989-03-15 MERCK SHARP & DOHME LTD. Oxazoles and thiazoles for the treatment of senile dementia
EP0323864A2 (en) * 1988-01-08 1989-07-12 Merck Sharp & Dohme Ltd. Lipophilic oxadiazoles
EP0462573A1 (en) * 1990-06-18 1991-12-27 Mitsubishi Chemical Corporation Pyrazolecarboxamide, insecticidal and miticidal composition, and fungicidal composition for use in agriculture and horticulture
WO1997030994A1 (en) * 1996-02-22 1997-08-28 Pfizer Research And Development Company, N.V./S.A. Oxa- and thia-diazole muscarinic receptor antagonists
WO1999019299A1 (en) * 1997-10-09 1999-04-22 Ortho-Mcneil Pharmaceutical, Inc. Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
US6242448B1 (en) * 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307141A2 (en) * 1987-09-10 1989-03-15 MERCK SHARP & DOHME LTD. Oxazoles and thiazoles for the treatment of senile dementia
EP0323864A2 (en) * 1988-01-08 1989-07-12 Merck Sharp & Dohme Ltd. Lipophilic oxadiazoles
EP0462573A1 (en) * 1990-06-18 1991-12-27 Mitsubishi Chemical Corporation Pyrazolecarboxamide, insecticidal and miticidal composition, and fungicidal composition for use in agriculture and horticulture
WO1997030994A1 (en) * 1996-02-22 1997-08-28 Pfizer Research And Development Company, N.V./S.A. Oxa- and thia-diazole muscarinic receptor antagonists
WO1999019299A1 (en) * 1997-10-09 1999-04-22 Ortho-Mcneil Pharmaceutical, Inc. Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
US6242448B1 (en) * 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands

Also Published As

Publication number Publication date
WO2008017827A2 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
WO2008017827A3 (en) Azole and thiazole derivatives and their uses
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
IL182010A0 (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
WO2008011453A3 (en) SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
EP2063889A4 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
EP2019649A4 (en) Compositions and methods for treating or preventing diseases of body passageways
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2009020802A3 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2008084223A3 (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
WO2007127263A3 (en) Therapeutic uses of urolithins
MX2009001494A (en) 2-aminobenzoxazole carboxamides as 5ht3 modulators.
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
EP1985302A4 (en) Medicament for treatment of tumor and the use thereof
WO2009074247A8 (en) Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
WO2007130824A3 (en) Fused heterocylic compounds and their use as mglur5 modulators
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
WO2009019294A3 (en) Bupropion hydrobromide and therapeutic applications
IL178165A0 (en) Use of ppr delta agonists for treating demyelinating diseases
WO2009030224A3 (en) Novel quinazoline compounds and the use thereof for treating cancerous diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789128

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07789128

Country of ref document: EP

Kind code of ref document: A2